| Nov 15 |
US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest Results
|
| Nov 12 |
Marinus Pharmaceuticals GAAP EPS of -$0.42 in-line, revenue of $8.54M misses by $0.81M
|
| Nov 12 |
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates
|
| Nov 12 |
Marinus Pharmaceuticals: Q3 Earnings Snapshot
|
| Nov 12 |
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
|
| Oct 25 |
Marinus downgraded after setback to late-stage trial
|
| Oct 25 |
Marinus’ clinical trial of ganaxolone fails to meet primary endpoint
|
| Oct 25 |
GSK invests $800M in manufacturing; Amgen sets small discount for Eylea biosimilar
|
| Oct 24 |
Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options
|
| Oct 24 |
Marinus tanks after late stage trial for treatment of seizures in TSC fails to meet main goal
|
